SS Innovations International (NASDAQ:SSII) Director Timothy Adams Acquires 300,000 Shares of Stock

SS Innovations International, Inc. (NASDAQ:SSII) Director Timothy Adams purchased 300,000 shares of the stock in a transaction that occurred on Friday, March 6th. The stock was acquired at an average cost of $3.99 per share, with a total value of $1,197,000.00. Following the completion of the acquisition, the director directly owned 5,331,902 shares of the company’s stock, valued at $21,274,288.98. This represents a 5.96% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

SS Innovations International Trading Down 5.6%

SSII stock opened at $4.42 on Wednesday. The stock has a market cap of $859.07 million and a P/E ratio of -88.40. SS Innovations International, Inc. has a twelve month low of $3.02 and a twelve month high of $22.42. The company’s 50 day moving average is $4.82 and its two-hundred day moving average is $6.05.

SS Innovations International (NASDAQ:SSII) last issued its earnings results on Tuesday, January 13th. The company reported $0.04 earnings per share (EPS) for the quarter. The business had revenue of $14.53 million during the quarter. SS Innovations International had a negative net margin of 32.10% and a negative return on equity of 34.13%.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of SS Innovations International in a report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Key Stories Impacting SS Innovations International

Here are the key news stories impacting SS Innovations International this week:

• Positive Sentiment: CEO Srivastava purchased 498,753 shares (~$2.0M) at ~$4.01, a small increase to his very large holding — insider buying often signals management confidence. SEC filing: Srivastava purchase
• Positive Sentiment: Director Timothy P. Adams bought 300,000 shares (~$1.2M at $3.99), a ~6% increase in his stake — another insider buy reinforcing management’s commitment. SEC filing: Adams purchase
• Positive Sentiment: Vice-Chair Dr. Frederic H. Moll acquired 501,253 shares (~$2.0M at $3.99), increasing his holding — further insider participation. SEC filing: Moll purchase
• Positive Sentiment: SS Innovations completed a private placement raising ~$18.6M (5.77M shares sold) to fund global expansion and working capital; Manipal Global Health Services led the institutional portion and insiders participated. Proceeds support U.S./EU market push while awaiting FDA review of the SSi Mantra. GlobeNewswire: Private placement
• Positive Sentiment: Company released Q4 and full‑year 2025 unaudited results highlighting strong growth in SSi Mantra installations, procedures and revenue — supports the growth narrative as the firm scales device adoption. GlobeNewswire: Q4/FY2025 results
• Neutral Sentiment: Quiver/market data indicates some institutional additions to SSII in recent quarters, which could provide longer‑term support but may not change near‑term volatility. QuiverQuant: Placement/ownership summary
• Negative Sentiment: The private placement included a material share issuance (5.77M shares) and unregistered securities (and warrants issued to a FINRA firm), creating dilution and some liquidity/registration constraints — a common reason for downward pressure. GlobeNewswire: Private placement terms
• Negative Sentiment: SSII’s growth depends on regulatory approvals (FDA 510(k) review expected mid‑2026 and CE marking efforts). Timing and outcome create execution risk that can keep the stock volatile. GlobeNewswire: Regulatory timeline

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of SSII. Handelsbanken Fonder AB increased its holdings in SS Innovations International by 9.3% in the fourth quarter. Handelsbanken Fonder AB now owns 120,000 shares of the company’s stock valued at $682,000 after buying an additional 10,198 shares in the last quarter. JNBA Financial Advisors purchased a new position in SS Innovations International in the 4th quarter valued at approximately $498,000. Inspire Investing LLC raised its holdings in SS Innovations International by 124.4% during the fourth quarter. Inspire Investing LLC now owns 82,773 shares of the company’s stock worth $470,000 after purchasing an additional 45,886 shares during the last quarter. Eversept Partners LP acquired a new stake in SS Innovations International in the fourth quarter valued at $428,000. Finally, AlphaCentric Advisors LLC purchased a new position in shares of SS Innovations International in the fourth quarter valued at $284,000.

About SS Innovations International

AVRA Medical Robotics, Inc develops and manufactures medical surgical devices. The company has a research agreement with the University of Central Florida to develop navigation and control technologies with applications in medical robotics. The company was formerly known as AVRA Surgical Microsystems, Inc and changed its name to AVRA Medical Robotics, Inc in November 2015. AVRA Medical Robotics, Inc was founded in 2015 and is based in Orlando, Florida.